The four major companies in the orthopedics space – Johnson & Johnson, Smith & Nephew PLC, Stryker Corp. and Zimmer Biomet Holdings Inc. – have all seen significant reductions in first-quarter revenues due to the delay of elective procedures as hospitals focused on treating COVID-19 patients.
With many US states taking steps to resume outpatient and inpatient elective surgeries under President Donald Trump’s three-part plan to reopen the country, companies are hoping to ramp up procedure volumes in the coming months. Analysts agree, however, that the negative financial impact of the delays will probably last for months, as customers are likely to reduce inventory and conserve cash
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?